A groundbreaking injectable HIV prevention drug will be available for just $40 a year in over 100 countries by 2027, thanks to agreements between Unitaid, the Gates Foundation, and Indian pharmaceutical companies.
A groundbreaking partnership aims to provide low-cost lenacapavir to millions at risk of HIV in low- and middle-income countries, potentially transforming HIV prevention efforts worldwide.
President Trump unveils a groundbreaking executive order aimed at slashing U.S. drug prices by matching them to those in developed countries. Will this initiative reshape the pharmaceutical landscape and benefit American patients?
